<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469128</url>
  </required_header>
  <id_info>
    <org_study_id>2016-2017PTBUE</org_study_id>
    <secondary_id>IRB Protocol CL-006</secondary_id>
    <nct_id>NCT03469128</nct_id>
  </id_info>
  <brief_title>Cognitive Processing Therapy vs. Sertraline for the Treatment of PTSD &amp; SUD in Egyptian Patients</brief_title>
  <official_title>Cognitive Processing Therapy Versus Sertraline for the Treatment of Post-traumatic Stress Disorder &amp; Substance Use Disorder Egyptian Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British University In Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British University In Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present research was aimed at comparing the effects of Cognitive Processing Therapy (CPT)&#xD;
      with the effects of Sertraline in treating patients who have dual diagnosis PTSD &amp; SUD. The&#xD;
      present study examines the extent to which CPT is effective in treating PTSD symptoms for&#xD;
      patients with PTSD and SUD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with co-occurrence PTSD &amp; SUD disorders were grouped into 3 groups: first: Cognitive&#xD;
      Processing Therapy (CPT) in which participants completed 12 sessions of CPT. Second: were&#xD;
      treated by Sertraline. Third: a placebo control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Data were obtained by interviewing 587 patients diagnosed with SUD. Patients were interviewed by a clinician and asked to complete: Mini-International Neuropsychiatric Interview (M.I.N.I), and Clinician-Administered PTSD Scale (CAPS). Patients with comorbid SUD and PTSD were asked to complete: The Brief Addiction Monitor (BAM), PTSD Checklist-Civilian (PCL-5), Beck Depression Inventory (BDI-II), and Timeline Follow Back Interview (TLFB). Patients with comorbid SUD and PTSD were randomized to one of the following groups: 1) received CPT. 2) received Sertraline. 3) the Placebo control group.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>This is a three-group, repeated-measure, parallel-group, Randomized Control Trial design. Patients, study psychiatrists, and assessors were blind to treatment condition assignment. Randomization blocks of three were used to maintain equal group size. The 3-month assessment serves as the post-treatment. Outcome assessments were PTSD severity, substance use severity, and depression. The pharmacy of Ain Shams Hospital created sertraline and matching placebo kits with single-identifier numbers based on a random code that was provided to an unblinded statistician who will instruct the psychiatrist how to distribute kits to patients.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Questionnaire</measure>
    <time_frame>3 Months</time_frame>
    <description>A psychological parameter will be measured to check the efficacy of CPT against medication for the treatment for co-current PTSD &amp; SUD. The groups will be examined to show if any significant reductions in PTSD and SUD symptoms was obtained over time.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Psychologic Manipulation</condition>
  <arm_group>
    <arm_group_label>Cognitive processing therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cognitive Processing Therapy (CPT) in which participants completed 12 sessions of CPT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with co-occurrence PTSD &amp; SUD disorders were treated by Sertraline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive processing therapy</intervention_name>
    <description>Psychological treatment for patients suffering from PTSD and SUD symptoms.</description>
    <arm_group_label>Cognitive processing therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Sertraline for the treatment of post-traumatic stress and SU disorders</description>
    <arm_group_label>Sertraline</arm_group_label>
    <other_name>SSRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Control</intervention_name>
    <description>Placebo Control</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with SUD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with other psychotic disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amani Elbarazi, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The British university in Egypt</affiliation>
  </overall_official>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>British University In Egypt</investigator_affiliation>
    <investigator_full_name>Amani Safwat Albrazi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>CPT</keyword>
  <keyword>SUD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03469128/Prot_SAP_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03469128/ICF_004.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

